The DOI matches its Crossref record, with a small difference in title or year; 251 of the 252 references it cites were found in a registry or an index.
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Open accessAbstract
Hypertrophic cardiomyopathy (HCM) is a genetic disorder that is characterized by left ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle with preserved or increased ejection fraction. It is commonly asymmetrical with the most severe hypertrophy involving the basal interventricular septum. Left ventricular outflow tract obstruction is present at rest in about one third of the patients and can be provoked in another third. The histological features of HCM include myocyte hypertrophy and disarray, as well as interstitial fibrosis. The hypertrophy is also frequently associated with left ventricular diastolic dysfunction. In the majority of patients, HCM has a relatively benign course. However, HCM is also an important cause of sudden cardiac death, particularly in adolescents and young adults. Nonsustained ventricular tachycardia, syncope, a family history of sudden cardiac death, and severe cardiac hypertrophy are major risk factors for sudden cardiac death. This complication can usually be averted by implantation of a cardioverter-defibrillator in appropriate high-risk patients. Atrial fibrillation is also a common complication and is not well tolerated. Mutations in over a dozen genes encoding sarcomere-associated proteins cause HCM. MYH7 and MYBPC3 , encoding β-myosin heavy chain and myosin-binding protein C, respectively, are the 2 most common genes involved, together accounting for ≈50% of the HCM families. In ≈40% of HCM patients, the causal genes remain to be identified. Mutations in genes responsible for storage diseases also cause a phenotype resembling HCM (genocopy or phenocopy). The routine applications of genetic testing and preclinical identification of family members represents an important advance. The genetic discoveries have enhanced understanding of the molecular pathogenesis of HCM and have stimulated efforts designed to identify new therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This clinical variability can, in part, be explained by the influence of modifiable cardiometabolic risk factors, such as obesity, diabetes, and hypertension [6].”
From Association of GLP-1 receptor agonist use with cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“Hypertrophic cardiomyopathy (HCM) is characterized by cardiac hypertrophy, a non-dilated left ventricle (LV), and a normal or increased EF.”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
A map of human genome variation from population-scale sequencing.
The 1000 Genomes Project Consortium (2010) · Nature · doi:10.1038/nature09534 · Cited by 7,877
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults
Maron, B. J., Gardin, J. M., Flack, J. M., Gidding, S. S., Kurosaki, T., & Bild, D. E. (1995) · Circulation · doi:10.1161/01.cir.92.4.785 · Cited by 2,274
Sudden Deaths in Young Competitive Athletes
Maron, B. J., Doerer, J. J., Haas, T. S., Tierney, D. M., & Mueller, F. O. (2009) · Circulation · doi:10.1161/circulationaha.108.804617 · Cited by 2,099
Sudden Death in Young Competitive Athletes: Clinical, Demographic, and Pathological Profiles
Maron, B. J. (1996) · JAMA · doi:10.1001/jama.1996.03540030033028 · Cited by 1,693
New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy
Semsarian, C., Ingles, J., Maron, M. S., & Maron, B. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.019 · Cited by 1,405
Geisterfer-Lowrance, A. A. T., Kass, S., Tanigawa, G., Vosberg, H.-P., McKenna, W., Seidman, C. E., & Seidman, J. G. (1990) · Cell · doi:10.1016/0092-8674(90)90274-i · Cited by 1,380
Richard, P., Charron, P., Carrier, L., Ledeuil, C., Cheav, T., Pichereau, C., Benaiche, A., Isnard, R., Dubourg, O., Burban, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000066323.15244.54 · Cited by 1,276
O'Mahony, C., Jichi, F., Pavlou, M., Monserrat, L., Anastasakis, A., Rapezzi, C., Biagini, E., Gimeno, J. R., Limongelli, G., McKenna, W. J., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht439 · Cited by 1,251
Research works printed but not linked: 2
- 10.1161/01.CIR.104.3.317 · DOI
- BROCK R. Functional obstruction of the left ventricle (acquired aortic subvalvar stenosis). Guys Hosp Rep. 1959;108:126–143.
Cited by
Sorted by citations
Items 501–600 of 1,001
Disease modeling of cardiac arrhythmias using human induced pluripotent stem cells
Liang, W., Gasparyan, L., Alqarawi, W., & Davis, D. R. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1575359 · Cited by 9
Life-threatening muscle complications of COL4A1-related disorder
Okano, S., Shimada, S., Tanaka, R., Okayama, A., Kajihama, A., Suzuki, N., Nakau, K., Takahashi, S., Matsumoto, N., Saitsu, H., et al. (2019) · Brain and Development · doi:10.1016/j.braindev.2019.09.001 · Cited by 10
INDUCED PLURIPOTENT STEM CELLS FOR MODELLING ENERGETIC ALTERATIONS IN HYPERTROPHIC CARDIOMYOPATHY.
Ramachandra, C. J. A., Ja, K. P. M. M., Lin, Y., SHIM, W. S. N., Boisvert, W. A., & Hausenloy, D. J. (2019) · PubMed · Cited by 10
Cardiotoxicity of immune checkpoint inhibitors: An updated review
Behravesh, S., Shomali, N., Danbaran, G. R., Aslani, S., Hemmatzadeh, M., Hosseinzadeh, R., Shabgah, A. G., & Mohammadi, H. (2020) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2081 · Cited by 11
Society for Cardiovascular Magnetic Resonance 2019 Case of the Week series
Dahiya, A., Chao, C., Younger, J. F., Kar, J., Baldwin, B. M., Cohen, M. V., Joseph, S., Chowdhry, A., Figarola, M. S., Malozzi, C. M., et al. (2021) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-020-00671-7 · Cited by 10
Lucarelli, K., Troisi, F., Scarcia, M., & Grimaldi, M. (2021) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytab446 · Cited by 10
Li, Z., Wang, Y., Li, L., He, H., Lin, L., Pan, M., Yang, T., & Liu, Q. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105330 · Cited by 10
Nollet, E. E., Algül, S., Goebel, M., Schlossarek, S., van der Wel, N. N., Jans, J. J. M., van de Wiel, M. A., Knol, J. C., Pham, T. V., Piersma, S. R., et al. (2023) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2023.100050 · Cited by 10
Federated Learning for Multi-Center Imaging Diagnostics: A Study in Cardiovascular Disease
Linardos, A., Kushibar, K., Walsh, S., Gkontra, P., & Lekadir, K. (2021) · doi:10.21203/rs.3.rs-688924/v1 · Cited by 9
Myosin modulators move forward with FDA approval of mavacamten
Chin, A. C., & Day, S. M. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00093-x · Cited by 9
Salmanipour, A., Jolfayi, A. G., Khadem, N. S., Rezaeian, N., Chalian, H., Mazloomzadeh, S., Adimi, S., & Asadian, S. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1246759 · Cited by 9
Zhang, Y., Yao, B., Guo, Y., Huang, S., Liu, J., Zhang, Y., Liang, C., Huang, J., Tang, Y., & Wang, X. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116169 · Cited by 9
Applying Artificial Intelligence for Phenotyping of Inherited Arrhythmia Syndromes
Sigfstead, S., Jiang, R., Avram, R., Davies, B., Krahn, A. D., & Cheung, C. C. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.04.014 · Cited by 9
Zdebik, N., Poręba, R., & Gać, P. (2024) · Biomedicines · doi:10.3390/biomedicines12061330 · Cited by 9
Mori, H., Xu, D., Shimoda, Y., Yuan, Z., Murakata, Y., Xi, B., Sato, K., Yamamoto, M., Tajiri, K., Ishizu, T., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-62530-0 · Cited by 9
Association of Liver Fibrosis-4 Index with Adverse Outcomes in Hypertrophic Cardiomyopathy Patients
Abdu, F. A., Mareai, R. M., Xiang, L., Galip, J., Mohammed, A., Zhang, W., Liu, L., Wang, C., Mohammed, A. A. S., Yin, G., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14977 · Cited by 9
Fan, H., Tan, X., Xu, S., Zeng, Y., Zhang, H., Shao, T., Zhao, R., Zhou, P., Bo, X., Fan, J., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01024-1 · Cited by 10
Comparison of Alcohol Septal Ablation With Mavacamten in Obstructive Hypertrophic Cardiomyopathy
Samhan, A., Saleh, D., Kim, E. Y., Hu, M., Mueller, K., Garza, A., Schormann, E., Bindra, P. H., Cheema, B. S., Fullenkamp, D. E., et al. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.12.024 · Cited by 9
Dong, Z., Tang, Y., Sun, P., Yin, G., Zhao, K., Ma, X., Yang, S., Wang, J., Xiang, X., Yang, K., et al. (2025) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.240009 · Cited by 9
Tian, Z., Li, X., Li, L., Zhang, Q., Wang, J., Shi, Y., Peng, D., Yang, P., Ma, W., Wang, F., et al. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00409-5 · Cited by 9
Heterogeneous Dysregulation of Myosin Super-Relaxation and Energetics in Hypertrophic Cardiomyopathy
Ochala, J., Feng, M., Wang, Q., Chaami, C., Nollet, E. E., Lewis, C. T. A., Hessel, A. L., Michels, M., Bedi, K. C., Margulies, K. B., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012614 · Cited by 9
Tian, Z., Li, L., Li, X., Zhang, Q., Peng, D., Ma, W., Yang, P. C., Wang, F., Cheng, X. C., Fu, Y., et al. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.05.015 · Cited by 9
Mahana, I., Mejia, A. T., Elman, M., Kamna, D., Nguyen, O., Volk, H., Chen, H., & Masri, A. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.042488 · Cited by 9
Measuring hypertrophy in neonatal rat primary cardiomyocytes and human iPSC-derived cardiomyocytes
Bourque, K., Hawey, C., Jones-Tabah, J., Pétrin, D., Martin, R., Sun, Y., & Hébert, T. E. (2021) · Methods · doi:10.1016/j.ymeth.2021.12.006 · Cited by 12
Pathogenic variant of RBM20 in a multiplex family with hypertrophic cardiomyopathy
Inagaki, N., Hayashi, T., Takei, Y., Kosuge, H., Suzuki, S., Tanimoto, K., Chikamori, T., & Kimura, A. (2022) · Human Genome Variation · doi:10.1038/s41439-022-00183-z · Cited by 9
Da'as, S. I., Hasan, W., Salem, R., Younes, N., Abdelrahman, D., Mohamed, I. A., Aldaalis, A., Temanni, R., Mathew, L. S., Lorenz, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168840 · Cited by 9
Zhong, G., Chen, C., Wu, S., Chen, J., Han, Y., Zhu, Q., Xu, M., Nie, Q., & Wang, L. (2023) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-23-112 · Cited by 9
Genomics and insurance in the United Kingdom: increasing complexity and emerging challenges
Dixon, P., Horton, R. H., Newman, W. G., McDermott, J. H., & Lucassen, A. (2024) · Health Economics Policy and Law · doi:10.1017/s1744133124000070 · Cited by 9
Diretriz sobre Diagnóstico e Tratamento da Cardiomiopatia Hipertrófica – 2024
Fernandes, F., Simões, M. V., Correia, E. D. B., Marcondes‐Braga, F. G., Coelho‐Filho, O. R., Mesquita, C. T., Mathias, W., Antunes, M. D. O., Arteaga-Fernández, E., Rochitte, C. E., et al. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240415 · Cited by 31
Hu, Y., Zou, Y., Qiao, L., & Lin, L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.030 · Cited by 9
The Brockenbrough – Braunwald – Morrow Sign
Trevino, A. R., & Buergler, J. M. (2014) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-10-1-34 · Cited by 9
Bailey, K. E., MacGowan, G. A., Tual‐Chalot, S., Phillips, L. C., Mohun, T. J., Henderson, D. J., Arthur, H. M., Bamforth, S. D., & Phillips, H. M. (2019) · JCI Insight · doi:10.1172/jci.insight.125172 · Cited by 9
RetractedNew insights provided by myofibril mechanics in inherited cardiomyopathies.
Lin, Y., Yap, J. J. L., Ramachandra, C. J. A., & Hausenloy, D. J. (2019) · PubMed · Cited by 9
Gallo, G., Mastromarino, V., Limongelli, G., Calcagni, G., Maruotti, A., Ragni, L., Valente, F., Musumeci, B., Adorisio, R., Rubino, M., et al. (2021) · Biomolecules · doi:10.3390/biom11030376 · Cited by 9
Liu, L., Shenoy, S., Jahng, J. W. S., Liu, Y., Knowles, J. W., Zhuge, Y., & Wu, J. C. (2021) · Stem Cell Research · doi:10.1016/j.scr.2021.102279 · Cited by 9
Diagnosis of Cardiac Abnormalities in Muscular Dystrophies
Bădilă, E., Lungu, I. I., Grumezescu, A. M., & Scafa‐Udriște, A. (2021) · Medicina · doi:10.3390/medicina57050488 · Cited by 9
Lončarić, F., García‐Canadilla, P., García‐Álvarez, A., Sanchís, L., Prat, S., Doltra, A., Quintana, E., Pereda, D., Dejea, H., Bonnin, A., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.670734 · Cited by 9
Pradeep, R., Akram, A., Proute, M. C., Kothur, N., Georgiou, P., Serhiyenia, T., Shi, W., Kerolos, M. E., & Mostafa, J. A. (2021) · Cureus · doi:10.7759/cureus.17548 · Cited by 9
Pollmann, K., Kaltenecker, E., Schleihauf, J., Ewert, P., Görlach, A., & Wolf, C. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225256 · Cited by 9
Manhas, A., Jahng, J. W. S., Vera, C. D., Shenoy, S., Knowles, J. W., & Wu, J. C. (2022) · Stem Cell Research · doi:10.1016/j.scr.2022.102774 · Cited by 9
Gyftopoulos, A. A., Chen, Y., Wang, L., Williams, C. H., Chun, Y. W., O’Connell, J. R., Perry, J. A., & Hong, C. C. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.866042 · Cited by 9
Melenovský, V., Kubánek, M., & Kačer, P. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12342 · Cited by 9
Left Ventricular Noncompaction
Oechslin, E. N., & Klaassen, S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.064 · Cited by 10
McMillan, S. N., Pitts, J. R. T., Barua, B., Winkelmann, D. A., & Scarff, C. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.12.637875 · Cited by 9
Stachera, M., Przybyło, P., Sznajder, K., & Gierlotka, M. J. (2021) · Polish Journal of Radiology · doi:10.5114/pjr.2021.112310 · Cited by 8
Targeting lipid metabolism as a new therapeutic strategy for inherited cardiomyopathies
Gaar-Humphreys, K. R., van den Brink, A., Wekking, M., Asselbergs, F. W., van Steenbeek, F. G., Harakaľová, M., & Pei, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1114459 · Cited by 8
Transcatheter Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy
Pierri, A., Albani, S., Merlo, M., Buongiorno, A. L., Ricotti, A., Grilli, G., Barbisan, D., Grossi, S., Rosa, C. D., Mabritto, B. M. T., et al. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.100899 · Cited by 8
Causes and consequences of DNA double-stranded breaks in cardiovascular disease
Marian, A. J. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05131-9 · Cited by 8
Self-citationWeber, N., Montag, J., Kowalski, K., Iorga, B. I., de la Roche, J., Holler, T., Wojciechowski, D., Wendland, M., Radocaj, A., Mayer, A. K., et al. (2024) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2024.11.007 · Cited by 8
Huang, S., Chen, Z., Li, H.-M., Zou, Y., Wang, B., Zhao, W., Zheng, L., Zhou, Z., Peng, X., & Tang, C. (2025) · Nutrients · doi:10.3390/nu17132209 · Cited by 8
From Rare Genetic Variants to Polygenic Risk: Understanding the Genetic Basis of Cardiomyopathies
Ruano, A. G., Sola-García, E., Martin-Istillarty, M., & Urbano-Moral, J. Á. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12070274 · Cited by 8
Glazer, A. M., Tabet, D. R., Parikh, V. N., Kroncke, B. M., Coté, A. G., Yamamoto, Y., Wang, Q., Muhammad, A., Lancaster, M. C., O’Neill, M. J., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01201-7 · Cited by 8
Kannan, D., Rajasingh, S., Madasamy, P., & Rajasingh, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178179 · Cited by 8
Human induced pluripotent stem cell-derived cardiomyocytes for disease modeling and drug discovery
Moriwaki, T., Tani, H., & Tohyama, S. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1687840 · Cited by 8
Becker, R. C., Owens, A. P., & Sadayappan, S. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.05.003 · Cited by 8
Ma, W., del Rio, C. L., Qi, L., Prodanović, M., Mijailovich, S. M., Zambataro, C., Gong, H., Shimkunas, R., Gollapudi, S. K., Nag, S., et al. (2023) · Biophysical Journal · doi:10.1016/j.bpj.2022.11.829 · Cited by 8
Precision and genomic medicine for dilated and hypertrophic cardiomyopathy
Nomura, S., & Ōno, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1137498 · Cited by 8
Evolving Strategies for the Management of Obstructive Hypertrophic Cardiomyopathy
Liang, L. W., Lumish, H. S., Sewanan, L. R., Shimada, Y. J., Maurer, M. S., Weiner, S. D., & Clerkin, K. J. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.04.024 · Cited by 8
Evaluation of mavacamten in patients with hypertrophic cardiomyopathy
Liao, H.-L., Liang, Y., & Liang, B. (2024) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001638 · Cited by 8
Harikrishnan, S., Koshy, L., Ganapathi, S., Jeemon, P., Das, N. K. R., Urulangodi, M., Madhuma, M., Vysakh, Y., Subran, A., & Lakshmikanth, L. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132273 · Cited by 8
Is Type 2 Diabetes Mellitus an Independent Risk Factor for Mortality in Hypertrophic Cardiomyopathy?
Hajouli, S., Belcher, A. M., Annie, F., & Elashery, A. R. (2024) · Cardiology Research · doi:10.14740/cr1659 · Cited by 8
Ali, S. A., Perera, G., Laird, J., Batorsky, R., Maron, M. S., Rivas, V. N., Stern, J. A., Harris, S. P., & Chin, M. T. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035780 · Cited by 8
Trenkwalder, T., Schunkert, H., & Reinhard, W. (2019) · Herz · doi:10.1007/s00059-019-04875-1 · Cited by 8
Jiang, W., Liu, Y., He, Z., Zhou, Y., Wang, C., Jiang, Z., & Zhou, W. (2020) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001322 · Cited by 8
Jansen, M., Christiaans, I., van der Crabben, S. N., Michels, M., Huurman, R., Hoedemaekers, Y. M., Dooijes, D., Jongbloed, J. D. H., Boven, L. G., Deprez, R. H. L., et al. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01539-w · Cited by 8
Qiu, H., Sun, Y., Pan, Z., Zhou, J., Wang, H., Wang, X., Cai, D., Fu, G., Gong, T., Jiang, C., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.647 · Cited by 8
Whole mitochondrial genome sequencing of Malaysian patients with cardiomyopathy
Kuan, S. W., Chua, K. H., Tan, E.-W., Tan, L. K., Loch, A., & Kee, B. P. (2022) · PeerJ · doi:10.7717/peerj.13265 · Cited by 8
Miyamoto, Y., Kubo, T., Ochi, Y., Baba, Y., Hirota, T., Yamasaki, N., Kawai, K., Yamamoto, K., Kondo, F., Bando, K., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0068 · Cited by 8
Prediction of the disease course in Friedreich ataxia
Hohenfeld, C., Terstiege, U., Dogan, I., Giunti, P., Parkinson, M. H., Mariotti, C., Nanetti, L., Fichera, M., Dürr, A., Ewenczyk, C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-23666-z · Cited by 8
Proteomic profiling of sudden cardiac death with acquired cardiac hypertrophy
Kakimoto, Y., Ueda, A., Ito, M., Tanaka, M., Kubota, T., Isozaki, S., & Osawa, M. (2023) · International Journal of Legal Medicine · doi:10.1007/s00414-023-03038-6 · Cited by 8
Campuzano, Ó., Fernández-Falgueras, A., Sarquella‐Brugada, G., César, S., Arbelo, E., García‐Álvarez, A., Jordà, P., Coll, M., Fiol, V., Iglesias, A., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00450 · Cited by 8
Contemporary review on pediatric hypertrophic cardiomyopathy: insights into detection and management
Shafqat, A., Shaik, A., Koritala, S., Mushtaq, A. H., Sabbah, B. N., Elshaer, A. N., & Baqal, O. J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1277041 · Cited by 7
Influence of Clinical Aspects and Genetic Factors on Feline HCM Severity and Development
Korobova, V. V., & Kruglova, Y. S. (2024) · Veterinary Sciences · doi:10.3390/vetsci11050214 · Cited by 7
Zhao, Q., Chen, Z., Qi, C., Xu, S., Ren, R., Li, W., Zhang, X., & Zhang, Y. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1421013 · Cited by 7
Pathogenic genes and clinical prognosis in hypertrophic cardiomyopathy
Hong, Y., Xi, H.-T., Yang, X.-Y., SU, W. W., & Li, X. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i1.99595 · Cited by 7
Ogieuhi, I. J., Ajekiigbe, V. O., ADEYEMI, B., Nwatamole, B. C., Ayodeji, K. B., Ugiomoh, O. M.-A., Odeniyi, T. A., Akingbola, A., Iyawe, E. P., Oladejo, O. O., et al. (2025) · The Egyptian Heart Journal · doi:10.1186/s43044-025-00652-0 · Cited by 7
Hua, X., Sun, Z., Wang, C., Cui, H., Shan, D., Tao, M., Cui, Z., Chang, Y., Bao, M., Mo, H., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.041401 · Cited by 8
Tan, Z., Wu, L., Fang, Y. M., Chen, P., Wan, R., Shen, Y., Hu, J., Jiang, Z., & Hong, K. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.670787 · Cited by 7
Khan, H. R., Rodwell, P., Taha, A. H., Goha, A. M., Ahmed, M., Thain, A., Somarakis, K., Al‐Atta, A., Erhayiem, B., Uddin, A., et al. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10030120 · Cited by 7
Gu, Z.-Y., Qian, Y., Chen, B., Wu, C., Zhao, L., Xue, S., Zhao, L., Wu, L., & Wang, Y. (2023) · Insights into Imaging · doi:10.1186/s13244-023-01479-6 · Cited by 7
Zalivina, I., Barwari, T., Yin, X., Langley, S. R., Barallobre‐Barreiro, J., Wakimoto, H., Zampetaki, A., Mayr, M., Avkiran, M., & Eminaga, S. (2023) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2023.100056 · Cited by 7
Rangwala, H. S., Fatima, H., Ali, M., Ahmed, S. T., Rangwala, B. S., & Abbas, S. R. (2023) · The Egyptian Heart Journal · doi:10.1186/s43044-023-00427-5 · Cited by 7
Arrhythmias and Hypertrophic Cardiomyopathy: Unravelling the Connection
Aggarwal, K., Boyapati, S. P., Valecha, J., Noor, A., Kanwal, F., Jain, R., & Kanagala, S. G. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x279223231227111737 · Cited by 7
Vanmali, A., Alhumaid, W., & White, J. A. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.02.029 · Cited by 7
Does Disopyramide Still Have a Place in the Management of Obstructive Hypertrophic Cardiomyopathy?
Corriveau, S., Heydari, B., & Garceau, P. (2024) · CJC Open · doi:10.1016/j.cjco.2024.03.006 · Cited by 7
Wang, S., Zhang, K., He, M., Guo, H., Cui, H. Z., Wang, S., & Lai, Y. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.102992 · Cited by 7
Jean‐Charles, P., Roy, B., Yu, S. M.-W., Pironti, G., Nagi, K., Mao, L., Kaur, S., Abraham, D., Maudsley, S. R., Rockman, H. A., et al. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00329.2024 · Cited by 7
Сергеевна, Ч. О., & Mershina, E. A. (2024) · Experimental Biology and Medicine · doi:10.3389/ebm.2024.10334 · Cited by 9
Fetisova, S., Melnik, O., Vasichkina, E. S., Вершинина, Т. Л., Kofeynikova, O. А., Kozyreva, A. A., Fomicheva, Y. V., Sokolnikova, P., Zhuk, S., Pervunina, T. M., et al. (2025) · Pediatric Research · doi:10.1038/s41390-025-03989-z · Cited by 7
Anti-arrhythmic therapy in patients with non-ischemic cardiomyopathy
Proietti, R., Russo, V., & AlTurki, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.004 · Cited by 7
Sex differences in cardiac magnetic resonance features in patients with hypertrophic cardiomyopathy
Romo, M. T. N., Cecconi, A., Olivera, M. J., Caballero, P., Hernández, S., Jiménez‐Borreguero, L. J., & Alfonso, F. (2020) · International journal of cardiac imaging · doi:10.1007/s10554-020-01880-y · Cited by 7
Rodgers, J. L., Vanthenapalli, S., & Panguluri, S. K. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30165 · Cited by 7
Dementyeva, E. V., Pavlova, S. V., Chernyavsky, A. M., & Zakian, S. M. (2021) · Stem Cell Research · doi:10.1016/j.scr.2021.102344 · Cited by 7
Cao, X., Jahng, J. W. S., Lee, C., Zha, Y., Wheeler, M. T., Sallam, K., & Wu, J. C. (2021) · Stem Cell Research · doi:10.1016/j.scr.2021.102455 · Cited by 7
Pai, S., Chadha, R., Logvinov, I. I., Brigham, T., Watt, K. D. S., Li, Z., Palmer, W. C., Blackshear, J. L., & Aniskevich, S. (2021) · Clinical Transplantation · doi:10.1111/ctr.14538 · Cited by 7
Abdelazeem, B., Abbas, K. S., Ahmad, S., Raslan, H., Labieb, F., & Savarapu, P. K. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2304141 · Cited by 7
Cuesta‐Llavona, E., Lorca, R., Rollé, V., Alonso, B., Iglesias, S., Rodríguez-Reguero, J., Duarte-Herrera, I. D., Pérez‐Oliveira, S., Junco-Vicente, A., García-Lago, C., et al. (2022) · Life · doi:10.3390/life12060818 · Cited by 7
Chen, J., Liu, G., Sun, W., Zheng, Y., Jin, J., Chen, S., Yuan, J., Gong, H., Luo, Q., & Yang, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.945198 · Cited by 7
Li, X., Fan, H., Song, X., Song, B., Liu, W., Dong, R., Zhang, H., Guo, S., Liang, H., Schrodi, S. J., et al. (2023) · Epigenetics · doi:10.1080/15592294.2023.2195307 · Cited by 7
Regulatory T Cells in Pathological Cardiac Hypertrophy: Mechanisms and Therapeutic Potential
Liu, L., Hu, J., Lei, H., Qin, H., Wang, C., Gui, Y., & Xu, D. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07463-y · Cited by 7
Metadata
- Authors
- Marian, A. J., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Center for Cardiovascular Genetics, Institute of Molecular Medicine, Department of Medicine, University of Texas Health Sciences Center at Houston (A.J.M.); Texas Heart Institute, Houston (A.J.M.); and TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (E.B.).
- ORCID
- Marian, Ali J.
- Venue
- Circulation Research
- Published
- 2017-09-15
- Volume
- 121
- Issue
- 7
- Pages
- 749-770
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- PMC
- PMC5654557
- OpenAlex
- W2756203218
- Cited by
- 1,403
- References
- 252
- Citations by year
- 2026: 175 · 2025: 226 · 2024: 219 · 2023: 199 · 2022: 153 · 2021: 174 · 2020: 103 · 2019: 83 · 2018: 61 · 2017: 6
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Circulation Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL088498, R01HL132401)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Effects of Exercise
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- hypertrophic cardiomyopathy, left ventricular hypertrophy, left ventricular outflow tract obstruction, sudden cardiac death, non-sustained ventricular tachycardia, syncope, cardioverter-defibrillator implantation, atrial fibrillation, sarcomere gene mutations, MYH7, MYBPC3, genetic testing, phenocopy, storage diseases, left ventricular diastolic dysfunction, interstitial fibrosis, molecular pathogenesis
- MeSH terms
- Animals, Biopsy, Cardiomyopathy, Dilated, DNA Mutational Analysis, Genetic Markers, Humans, Mutation, Myocardium, Phenotype, Predictive Value of Tests, Prognosis, Risk Factors, Ventricular Function, Left, Risk Assessment, Genetic Predisposition to Disease, Molecular Diagnostic Techniques, Cardiac Imaging Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
